ATE269336T1 - Steroidrezeptor-modulator verbindungen und methoden - Google Patents

Steroidrezeptor-modulator verbindungen und methoden

Info

Publication number
ATE269336T1
ATE269336T1 AT00113829T AT00113829T ATE269336T1 AT E269336 T1 ATE269336 T1 AT E269336T1 AT 00113829 T AT00113829 T AT 00113829T AT 00113829 T AT00113829 T AT 00113829T AT E269336 T1 ATE269336 T1 AT E269336T1
Authority
AT
Austria
Prior art keywords
compounds
steroid receptor
methods
receptor modulator
disclosed
Prior art date
Application number
AT00113829T
Other languages
English (en)
Inventor
Todd K Jones
James E Edwards
Sarah J West
Christopher M Tegley
Lin Zhi
Original Assignee
Ligand Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/462,643 external-priority patent/US5696130A/en
Application filed by Ligand Pharm Inc filed Critical Ligand Pharm Inc
Application granted granted Critical
Publication of ATE269336T1 publication Critical patent/ATE269336T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal (AREA)
  • Optical Modulation, Optical Deflection, Nonlinear Optics, Optical Demodulation, Optical Logic Elements (AREA)
  • Peptides Or Proteins (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00113829T 1994-12-22 1995-12-13 Steroidrezeptor-modulator verbindungen und methoden ATE269336T1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US36352994A 1994-12-22 1994-12-22
US08/462,643 US5696130A (en) 1994-12-22 1995-06-05 Tricyclic steroid receptor modulator compounds and methods
US08/464,541 US5688810A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,546 US5693647A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,556 US5696133A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/465,429 US5696127A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/464,360 US5693646A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods
US08/463,231 US5688808A (en) 1994-12-22 1995-06-05 Steroid receptor modulator compounds and methods

Publications (1)

Publication Number Publication Date
ATE269336T1 true ATE269336T1 (de) 2004-07-15

Family

ID=27575415

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00113829T ATE269336T1 (de) 1994-12-22 1995-12-13 Steroidrezeptor-modulator verbindungen und methoden
AT95944089T ATE252560T1 (de) 1994-12-22 1995-12-13 Steroidrezeptor-modulator verbindungen und methoden

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT95944089T ATE252560T1 (de) 1994-12-22 1995-12-13 Steroidrezeptor-modulator verbindungen und methoden

Country Status (17)

Country Link
EP (7) EP1043326A1 (de)
JP (2) JPH10510840A (de)
CN (2) CN1626534A (de)
AT (2) ATE269336T1 (de)
AU (1) AU717251B2 (de)
BR (1) BR9510486A (de)
CA (1) CA2208347A1 (de)
CZ (1) CZ176197A3 (de)
DE (2) DE69531998T2 (de)
DK (1) DK0800519T3 (de)
ES (1) ES2208699T3 (de)
HU (1) HUT78117A (de)
NO (5) NO310617B1 (de)
NZ (1) NZ300739A (de)
PT (1) PT800519E (de)
RU (1) RU2191774C2 (de)
WO (1) WO1996019458A2 (de)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2168650T3 (es) * 1996-06-27 2002-06-16 Ligand Pharm Inc Compuestos y metodos moduladores de receptores de androgenos.
US6017924A (en) 1996-06-27 2000-01-25 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
AUPO427196A0 (en) * 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
WO1998027986A1 (en) * 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
US6291442B1 (en) 1998-02-03 2001-09-18 The General Hospital Corporation Pharmacological modulators of voltage-gated potassium ion channels
US6380207B2 (en) 1998-02-13 2002-04-30 Abbott Laboratories Glucocortiocoid-selective antiinflammatory agents
US6506766B1 (en) * 1998-02-13 2003-01-14 Abbott Laboratories Glucocortiocoid-selective antinflammatory agents
HUP0100460A3 (en) * 1998-02-13 2003-03-28 Ligand Pharmaceuticals Inc San Glucocorticoid-selective anti-inflammatory agents
US6001846A (en) * 1998-02-17 1999-12-14 Ligand Pharmaceuticals Incorporated Process for the preparation of 1,2-dihydroquinolines
US6093825A (en) * 1998-05-27 2000-07-25 American Home Products Methods for preparation of 1,2-dihydroquinolines
US6093826A (en) 1998-06-08 2000-07-25 Ligand Pharmaceuticals Incorporated Process for the preparation of C(5)-substituted 1,2-dihydro-5H-chromeno[3,4-f] quinolines
CA2334545A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
WO2000066560A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
CA2371273A1 (en) * 1999-05-04 2000-11-09 Andrew Fensome Tetracyclic progesterone receptor modulator compounds and methods
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
CA2371726A1 (en) * 1999-05-04 2000-11-09 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
NZ515353A (en) * 1999-05-04 2004-03-26 Ligand Pharm Inc Cyclothiocarbamate derivatives as progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
BR0013597A (pt) 1999-08-27 2002-07-16 Ligand Pharm Inc Compostos e métodos moduladores de receptor de androgênio
AU6941200A (en) 1999-08-27 2001-03-26 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido(3,2-g)quinoline compounds as androgen receptor modulators
US6566372B1 (en) * 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
HUP0202429A3 (en) * 1999-08-31 2004-04-28 Schering Ag Use of mesoprogestins (progesterone receptor modulators) for the preparation of pharmaceutical compositions for the treatment and prevention of benign hormone dependent gynecological disorders
PE20010647A1 (es) 1999-09-14 2001-06-23 Lilly Co Eli Moduladores de receptores de retinoide x (rxr) con perfil farmacologico mejorado
AU7558900A (en) * 1999-10-14 2001-04-23 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2004515462A (ja) * 2000-06-28 2004-05-27 ブリストル−マイヤーズ スクイブ カンパニー 核ホルモン・レセプタ機能のモジュレーターとしての縮合環式化合物
IL154408A0 (en) * 2000-08-23 2003-09-17 Akzo Nobel Nv 10-ARYL-11-H BENZO [b] FLUORENE DERIVATIVES AND ANALOGS FOR MEDICINAL USE
AU2001286243A1 (en) * 2000-09-14 2002-03-26 Kaken Pharmaceutical Co., Ltd. Tetrahydroquinoline compounds
EE200300108A (et) * 2000-09-19 2005-02-15 Bristol-Myers Squibb Company Kondenseerunud heterotsüklilised suktsiinimiidiühendid ja nende analoogid kui tuuma hormooniretseptori funktsiooni modulaatorid
US7026484B2 (en) 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US7214690B2 (en) 2001-02-23 2007-05-08 Ligand Pharmaceuticals Incorporated Tricyclic quinolinone and tricyclic quinoline androgen receptor modulator compounds and methods
US6608216B2 (en) 2001-06-29 2003-08-19 Abbott Laboratories Process for the preparation of chiral glucocorticoid receptor agents
WO2003002548A1 (en) * 2001-06-29 2003-01-09 Abbott Laboratories A process for the preparation of chiral glucocorticoid receptor agents
JP4523273B2 (ja) 2001-07-02 2010-08-11 ナームローゼ・フエンノートチヤツプ・オルガノン テトラヒドロキノリン誘導体
JP2003073374A (ja) * 2001-08-31 2003-03-12 Kaken Pharmaceut Co Ltd ２環性芳香族アミン誘導体
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6960581B2 (en) 2002-01-14 2005-11-01 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations, and uses thereof
TW200304371A (en) 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
KR101088352B1 (ko) 2002-02-28 2011-11-30 유니버시티 오브 테네시 리서치 파운데이션 다치환된 선택적 안드로겐 수용체 조절자 및 이를 사용하는 방법
JP2006508893A (ja) 2002-03-15 2006-03-16 イーライ・リリー・アンド・カンパニー ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−２−オン誘導体
CA2477764A1 (en) 2002-03-26 2003-10-09 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
PT1490062E (pt) 2002-03-26 2008-01-30 Boehringer Ingelheim Pharma Miméticos de glucocorticóides, métodos para a sua preparação, composições farmacêuticas e suas utilizações
WO2003090672A2 (en) * 2002-04-26 2003-11-06 Ortho-Mcneil Pharmaceutical, Inc. 2-(quinolonyl)-fused heterocycles as androgen receptor modulators
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ATE403648T1 (de) * 2002-08-21 2008-08-15 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
JP2006506445A (ja) 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
MXPA05003800A (es) 2002-10-11 2005-06-08 Ligand Pharm Inc 5-(1¦,1¦-cicloalquil/alquenil)metiliden 1,2-dihidro-5h- cromeno[3,4f]quinolinas como compuestos moduladores de receptor de progesterona selectivos.
MXPA05003721A (es) 2002-10-11 2005-06-17 Ligand Pharm Inc Derivados de 5-cicloalquenilo-5h-cromeno[3,4-f]quinolina como compuestos moduladores, selectivos de receptores de progesterona.
DE20301728U1 (de) 2002-10-11 2004-03-11 Ligand Pharmaceuticals, Inc., San Diego 5-substituierte 7,9-Difluor-5H-Chromeno(3,4-f) -Chinolin-Verbindungen als selektive Progesteronrezeptormodulator-Verbindungen
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
TWI322012B (en) * 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
TWI306855B (en) 2002-12-20 2009-03-01 Organon Nv Tetrahydroquinoline derivatives
CA2512257A1 (en) 2003-01-03 2004-07-29 Boehringer Ingelheim Pharmaceuticals, Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
EA200501376A1 (ru) * 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
CA2536349A1 (en) 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
ATE366726T1 (de) 2003-10-16 2007-08-15 Boehringer Ingelheim Pharma Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
US7256208B2 (en) 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7388027B2 (en) 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2005090282A1 (en) 2004-03-12 2005-09-29 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto
EP1836166B1 (de) 2004-12-27 2009-06-17 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid-mimetika, verfahren zu deren herstellung, pharmazeutische zusammensetzungen und deren verwendung
BRPI0609191B8 (pt) 2005-06-17 2021-05-25 Ligand Pharm Inc métodos e compostos moduladores de receptor de androgênio
US7709516B2 (en) 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
JP4825636B2 (ja) * 2005-09-14 2011-11-30 参天製薬株式会社 グルココルチコイド受容体結合活性を有する新規１，２−ジヒドロキノリン誘導体
CN102229562B (zh) 2005-09-14 2013-11-13 参天制药株式会社 具有糖皮质激素受体结合活性的1,2-二氢喹啉衍生物
US20090203725A1 (en) * 2005-12-21 2009-08-13 Cornelis Arjan Van Oeveren Androgen Receptor Modulator Compounds and Methods
WO2008059865A1 (fr) 2006-11-14 2008-05-22 Santen Pharmaceutical Co., Ltd. Nouveau dérivé 1,2-dihydroquinoline comprenant un groupe alkyle inférieur phénylchalcogéno substitué et un groupe phényle introduit par un ester en tant que substituants
BRPI0720131A2 (pt) 2006-12-06 2014-02-04 Boehringer Ingelheim Int Glicocorticoides miméticos, métodos para fazê-los, composições farmacêuticas e usos dos mesmos.
TWI410422B (zh) * 2007-01-15 2013-10-01 Mitsubishi Tanabe Pharma Corp 縮合四氫喹啉衍生物及其醫藥用途
JP2008255112A (ja) * 2007-03-13 2008-10-23 Santen Pharmaceut Co Ltd ２，２，４−トリメチル−６−フェニル−１，２−ジヒドロキノリン誘導体からなるグルココルチコイド受容体アゴニスト
US9284345B2 (en) 2007-04-12 2016-03-15 Endorecherche, Inc. 17alpha-substituted steroids as systemic antiandrogens and selective androgen receptor modulators
WO2009103007A2 (en) * 2008-02-13 2009-08-20 Ligand Pharmaceuticals Incorporated Steroid hormone receptor modulator compounds and methods
BRPI0912171B8 (pt) * 2008-05-12 2021-05-25 Ayumi Pharmaceutical Corp composto ativador de receptor de glicocorticoide, e, composição
WO2009149139A1 (en) 2008-06-06 2009-12-10 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP2130831A1 (de) 2008-06-06 2009-12-09 InterMed Discovery GmbH CDC25-Hemmer
CN102239149B (zh) 2008-10-06 2015-05-13 约翰·霍普金斯大学 喹啉化合物作为血管新生、人类甲硫氨酰氨肽酶、以及sirt1的抑制剂,以及治疗病症的方法
CN103613538B (zh) * 2013-11-22 2015-05-20 山东斯递尔化工科技有限公司 一种2,2,4-三甲基-1,2-二氢化喹啉聚合体的催化合成工艺
US9682960B2 (en) 2013-12-19 2017-06-20 Endorecherche, Inc. Non-steroidal antiandrogens and selective androgen receptor modulators with a pyridyl moiety
JP6821582B2 (ja) 2015-03-02 2021-01-27 コーセプト セラピューティクス， インコーポレイテッド Ａｃｔｈ分泌腫瘍を処置するための糖質コルチコイドレセプターアンタゴニストおよびソマトスタチンアナログの使用
EP3277281B1 (de) 2015-03-30 2022-01-05 Corcept Therapeutics, Inc. Verwendung von glukokortikoid-rezeptorantagonisten in kombination mit glukokortikoiden zur behandlung von nebenniereninsuffizienz
WO2017027851A1 (en) 2015-08-13 2017-02-16 Corcept Therapeutics, Inc. Method for differentially diagnosing acth-dependent cushing's syndrome
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome
CN106397317B (zh) * 2016-09-26 2019-03-22 天津师范大学 1,2,3,4-四氢喹啉化合物及其合成方法与应用
AU2018244928B2 (en) 2017-03-31 2023-10-19 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat cervical cancer
US11213526B2 (en) 2017-06-20 2022-01-04 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
CN107805248A (zh) * 2017-11-01 2018-03-16 长春海谱润斯科技有限公司 一种含有苯并咪唑结构的衍生物及其制备方法和有机电致发光器件
CN111499607B (zh) * 2019-01-30 2022-04-19 哈尔滨工业大学（深圳） 一种六元芳基内酯或六元芳基内酰胺化合物的制备方法
EP4263807A2 (de) 2020-12-18 2023-10-25 Instil Bio (Uk) Limited Verarbeitung von tumorinfiltrierenden lymphozyten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635941A (en) * 1969-04-01 1972-01-18 Eastman Kodak Co Disperse mono azo dyes containing an acylamidotetrahydroquinoline group
GB1379387A (en) * 1970-12-11 1975-01-02 Agfa Gevaert Photoconductive recording materials
US3907507A (en) * 1971-04-26 1975-09-23 Heliodoro Monroy Rivera Novel apparatus for the obtention of substituted 1,2-dihydroquinolines
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
ES2245660T3 (es) * 1990-11-30 2006-01-16 Otsuka Pharmaceutical Co., Ltd. Derivados de azol y su utilizacion como inhibidores de los radicales superoxidos.
JPH04316557A (ja) * 1991-04-16 1992-11-06 Kyorin Pharmaceut Co Ltd ６−アリール環状アントラニル酸誘導体

Also Published As

Publication number Publication date
DE69531998D1 (de) 2003-11-27
HUT78117A (hu) 1999-11-29
NO20003551L (no) 1997-08-14
EP1382597A2 (de) 2004-01-21
NO20003534L (no) 1997-08-14
DK0800519T3 (da) 2004-03-01
CN1175247A (zh) 1998-03-04
JP2007217418A (ja) 2007-08-30
WO1996019458A3 (en) 1996-12-12
NO313049B1 (no) 2002-08-05
NO20003550D0 (no) 2000-07-10
NO972591D0 (no) 1997-06-06
AU717251B2 (en) 2000-03-23
CN1626534A (zh) 2005-06-15
ATE252560T1 (de) 2003-11-15
PT800519E (pt) 2004-03-31
RU2191774C2 (ru) 2002-10-27
EP1382597A3 (de) 2004-04-07
NO310617B1 (no) 2001-07-30
EP1041066A1 (de) 2000-10-04
CN1172917C (zh) 2004-10-27
DE69533180T2 (de) 2005-07-14
NO312162B1 (no) 2002-04-02
NO312098B1 (no) 2002-03-18
EP1043325A1 (de) 2000-10-11
DE69531998T2 (de) 2004-07-22
NO20003552D0 (no) 2000-07-10
EP1043326A1 (de) 2000-10-11
CA2208347A1 (en) 1996-06-27
EP0800519B1 (de) 2003-10-22
NO20003550L (no) 1997-08-14
DE69533180D1 (de) 2004-07-22
EP1041071A1 (de) 2000-10-04
JPH10510840A (ja) 1998-10-20
NO972591L (no) 1997-08-14
NZ300739A (en) 2000-05-26
ES2208699T3 (es) 2004-06-16
EP1043325B1 (de) 2004-06-16
NO20003551D0 (no) 2000-07-10
WO1996019458A2 (en) 1996-06-27
EP1043315A1 (de) 2000-10-11
NO20003552L (no) 1997-08-14
EP0800519A1 (de) 1997-10-15
CZ176197A3 (cs) 1998-09-16
AU4597796A (en) 1996-07-10
BR9510486A (pt) 1998-06-02
NO20003534D0 (no) 2000-07-07

Similar Documents

Publication Publication Date Title
DE69533180D1 (de) Steroidrezeptor-Modulator Verbindungen und Methoden
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
ATE209207T1 (de) Androgen rezeptor modulator verbindungen und verfahren
WO2000066590A3 (en) Tetracyclic progesterone receptor modulator compounds and methods
DK0873295T3 (da) Dimer-selektive RXR-modulatorer og fremgangsmåder til deres anvendelse
BG106142A (en) Glucocorticoid receptor modulators
DE69728585D1 (de) Mittel gegen Juckreiz
GT199700009AA (es) Terapia combinada para la osteoporosis
DK0751939T3 (da) Naphthylamider som centralnervesystemmidler
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
MX9101958A (es) Inhibidores de acat de urea de aminosulfonilo
NO20014855L (no) N-(2-fenyl-4-aminobutyl)-1-naftamider som neurokinin-1- reseptorantagonister
DK0996435T3 (da) Aminosyrederivater anvendelige til behandling af slagtilfælde
DE69718146D1 (de) At1 rezeptor antagonist zur anregung von apoptosis
BR0206844A (pt) Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos
CA2259031A1 (en) Androgen receptor modulator compounds and methods

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties